CA2221623A1 - Continuous selective clonogenic expansion of relatively undifferentiated cells - Google Patents
Continuous selective clonogenic expansion of relatively undifferentiated cells Download PDFInfo
- Publication number
- CA2221623A1 CA2221623A1 CA002221623A CA2221623A CA2221623A1 CA 2221623 A1 CA2221623 A1 CA 2221623A1 CA 002221623 A CA002221623 A CA 002221623A CA 2221623 A CA2221623 A CA 2221623A CA 2221623 A1 CA2221623 A1 CA 2221623A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- chamber
- population
- fluid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003021 clonogenic effect Effects 0.000 title claims abstract description 12
- 239000011324 bead Substances 0.000 claims abstract description 71
- 230000027455 binding Effects 0.000 claims abstract description 63
- 239000012530 fluid Substances 0.000 claims abstract description 53
- 235000015097 nutrients Nutrition 0.000 claims abstract description 35
- 238000003306 harvesting Methods 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 102000036639 antigens Human genes 0.000 claims abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 263
- 238000000034 method Methods 0.000 claims description 72
- 239000007822 coupling agent Substances 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 25
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 22
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 22
- 239000003102 growth factor Substances 0.000 claims description 18
- 230000003993 interaction Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000006227 byproduct Substances 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 6
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 108090001008 Avidin Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 230000000707 stereoselective effect Effects 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 239000013618 particulate matter Substances 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 230000001360 synchronised effect Effects 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000001143 conditioned effect Effects 0.000 claims description 2
- 230000000925 erythroid effect Effects 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 description 24
- 230000008569 process Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 230000004663 cell proliferation Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 210000003995 blood forming stem cell Anatomy 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 210000005087 mononuclear cell Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000001994 activation Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- -1 e.g. Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 108010087904 neutravidin Proteins 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920002145 PharMed Polymers 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000005465 channeling Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- ZKTPOUXCUHYLDZ-SAYNGHPTSA-N C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NCCCCNC(=O)C1CCC(CC1)CN1C(C=CC1=O)=O Chemical compound C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)(=O)NCCCCNC(=O)C1CCC(CC1)CN1C(C=CC1=O)=O ZKTPOUXCUHYLDZ-SAYNGHPTSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Sustainable Development (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/446,165 US5674750A (en) | 1995-05-19 | 1995-05-19 | Continuous selective clonogenic expansion of relatively undifferentiated cells |
| US08/446,165 | 1995-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2221623A1 true CA2221623A1 (en) | 1996-11-21 |
Family
ID=23771556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002221623A Abandoned CA2221623A1 (en) | 1995-05-19 | 1996-05-17 | Continuous selective clonogenic expansion of relatively undifferentiated cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5674750A (enExample) |
| EP (1) | EP0830448A4 (enExample) |
| JP (1) | JPH11511654A (enExample) |
| AU (1) | AU5797496A (enExample) |
| CA (1) | CA2221623A1 (enExample) |
| WO (1) | WO1996036696A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925567A (en) * | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
| US6100043A (en) * | 1995-08-04 | 2000-08-08 | The Perkin-Elmer Corporation | Recombinant clone selection system |
| US5843656A (en) * | 1995-08-07 | 1998-12-01 | The Perkin-Elmer Corporation | Recombinant clone selection system |
| AU6844696A (en) * | 1995-08-07 | 1997-03-05 | Perkin-Elmer Corporation, The | Recombinant clone selection system |
| WO1998025634A1 (en) * | 1996-12-10 | 1998-06-18 | Hadasit Medical Research Services & Development Company Ltd. | Serum-derived factor inducing cell differentiation and medical uses thereof |
| US20020034819A1 (en) * | 1998-02-23 | 2002-03-21 | Alan K. Smith | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses |
| BR9914465A (pt) | 1998-09-29 | 2001-10-09 | Gamida Cell Ltd | Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células |
| US7585323B2 (en) | 2000-05-05 | 2009-09-08 | Medlden, Llc | In vitro mechanical loading of musculoskeletal tissues |
| US7811557B1 (en) | 2000-10-27 | 2010-10-12 | Viacell, Inc. | Methods for improving central nervous system functioning |
| IL160030A0 (en) * | 2001-07-23 | 2004-06-20 | Viacell Inc | Treatment of muscular dystrophy with cord blood cells |
| AU2002363322A1 (en) * | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| JP2005536179A (ja) * | 2001-11-09 | 2005-12-02 | バイアセル インコーポレーティッド | 細胞懸濁液の製造方法 |
| US7169278B2 (en) * | 2002-01-21 | 2007-01-30 | Tecan Trading Ag | Apparatus and separation media for separating particles in free-flow electrophoresis |
| US7169275B2 (en) * | 2002-01-21 | 2007-01-30 | Tecan Trading Ag | Method for separating particles in free flow electrophoresis |
| IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
| US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
| US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
| IL161903A0 (en) * | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| EP1708757A4 (en) * | 2003-12-19 | 2007-01-17 | Viacell Inc | USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE |
| US20070298015A1 (en) * | 2004-04-28 | 2007-12-27 | Viacell, Inc. | Treatment of Muscular Dystrophy with Mobilized Peripheral Blood Pluripotent Cells |
| WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| WO2006116793A1 (en) | 2005-05-04 | 2006-11-09 | Australian Stem Cell Centre Limited | Selecting, culturing and creating lineage committed hematopoietic stem cells |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| JP2012533519A (ja) | 2009-06-18 | 2012-12-27 | エムシーツー セル エイピーエス | 骨髄細胞外マトリックス抽出物およびその治療上の使用 |
| WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| JP6348848B2 (ja) | 2012-02-13 | 2018-06-27 | ガミダ セル リミテッド | 間葉系幹細胞の増殖 |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| CN115011556B (zh) * | 2022-08-10 | 2022-10-25 | 山东省齐鲁干细胞工程有限公司 | 一种脐带血造血干细胞的分离方法 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514499A (en) * | 1983-02-04 | 1985-04-30 | Corning Glass Works | Cell culture using a monolithic support |
| US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| WO1991016116A1 (en) * | 1990-04-23 | 1991-10-31 | Cellpro Incorporated | Immunoselection device and method |
| JPH07503127A (ja) * | 1991-10-23 | 1995-04-06 | セルプロ インコーポレイテッド | 幹細胞を選択的に増加する方法 |
| US5460964A (en) * | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| DE4240635C2 (de) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren |
-
1995
- 1995-05-19 US US08/446,165 patent/US5674750A/en not_active Expired - Lifetime
-
1996
- 1996-05-17 EP EP96914694A patent/EP0830448A4/en not_active Withdrawn
- 1996-05-17 WO PCT/US1996/007195 patent/WO1996036696A1/en not_active Ceased
- 1996-05-17 AU AU57974/96A patent/AU5797496A/en not_active Abandoned
- 1996-05-17 JP JP8535103A patent/JPH11511654A/ja not_active Ceased
- 1996-05-17 CA CA002221623A patent/CA2221623A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996036696A1 (en) | 1996-11-21 |
| EP0830448A4 (en) | 2001-12-05 |
| US5674750A (en) | 1997-10-07 |
| EP0830448A1 (en) | 1998-03-25 |
| AU5797496A (en) | 1996-11-29 |
| JPH11511654A (ja) | 1999-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5674750A (en) | Continuous selective clonogenic expansion of relatively undifferentiated cells | |
| US6338942B2 (en) | Selective expansion of target cell populations | |
| AU685743B2 (en) | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietic cells | |
| JP3692147B2 (ja) | フィルターデバイス | |
| US5728581A (en) | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein | |
| US5804442A (en) | Process for preparing macrophages, kits, and composition for the use of this process | |
| JP2002535981A (ja) | 造血幹細胞および／または前駆細胞を維持および増加するための方法および装置 | |
| JPH078274A (ja) | 膜バイオリアクター中の物質移動を改良する方法及び装置 | |
| DE69232682T2 (de) | Verfahren zur selektiven vermehrung von cd34 positiven zellen | |
| EP4314244B1 (en) | Cell capture and expansion | |
| US5906940A (en) | Culturing cells on macroporous glass carriers coated with gelatin, extracellular matrix protein and stromal cells | |
| JP2003510068A (ja) | 細胞を培養するための方法および装置 | |
| AU687531B2 (en) | Flow-through bioreactor with grooves for cell retention | |
| EP1479760A1 (de) | Künstliches Immunorgan | |
| EP3362550A1 (en) | Method of manufacturing cells using a hollow fiber bioreactor | |
| KR100250630B1 (ko) | 생물학적 인공 간 | |
| Pierson et al. | Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor | |
| JPH08511173A (ja) | バイオリアクターのための培養培地添加物 | |
| EP1270719A2 (en) | Cell population containing non-fetal hemangioblasts and method for producing same | |
| WO1991004317A1 (en) | Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy | |
| AU752573B2 (en) | Selective expansion of target cell populations | |
| AU711528B2 (en) | Continuous selective clonogenic expansion of relatively undifferentiated cells | |
| Pierson et al. | Population dynamics of human activated natural killer cells in culture | |
| CA2221433A1 (en) | Selective expansion of target cell populations | |
| JPH0576364A (ja) | 動物遊離細胞の固定化物、固定化方法および培養方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |